Role of the renin-angiotensin system and aldosterone on cardiometabolic syndrome

International Journal of Hypertension

Volumn 2011, Issue , 2011, Pages

  Stiefel, P ^a   Vallejo Vaz, A J ^a   Garcia Morillo S ^a   Villar, J ^a  

^a CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; RENIN;

ADIPOSE TISSUE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; FUNCTIONAL GENOMICS; HEART HYPERTROPHY; HEART PROTECTION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANT HYPERTENSION; REVIEW; SODIUM RETENTION; SYMPATHETIC TONE; TISSUE INTERACTION; TISSUE REGENERATION;

EID: 84857052216     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.4061/2011/685238     Document Type: Review

References (84)

1. Brown C. D., Higgins M., Donato K. A., Rohde F. C., Garrison R., Obarzanek E., Ernst N. D., Horan M., Body mass index and the prevalence of hypertension and dyslipidemia. Obesity Research 2000 8 9 605 619 2-s2.0-0034568976
2. Alberti K. G., George.Alberti@newcastle.ac.uk Zimmet P., Shaw J., The metabolic syndromea new worldwide definition. Lancet 2005 366 9491 1059 1062 10.1016/S0140-6736(05)67402-8 (Pubitemid 41338752)
3. Carr D. B., Utzschneider K. M., Hull R. L., Kodama K., Retzlaff B. M., Brunzell J. D., Shofer J. B., Fish B. E., Knopp R. H., Kahn S. E., Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004 53 8 2087 2094 2-s2.0-3242795814 10.2337/diabetes.53.8.2087 (Pubitemid 38970759)
4. Neels J. G., Olefsky J. M., Inflamed fat: what starts the fire? Journal of Clinical Investigation 2006 116 1 33 35 2-s2.0-31044447347 10.1172/JCI27280 (Pubitemid 43121788)
5. Weisberg S. P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R. L., Ferrante A. W., CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Journal of Clinical Investigation 2006 116 1 115 124 2-s2.0-31044456529 10.1172/JCI24335 (Pubitemid 43121796)
6. Ginsberg H. N., Insulin resistance and cardiovascular disease. Journal of Clinical Investigation 2000 106 4 453 458 2-s2.0-0033860359 (Pubitemid 30666377)
7. Stas S., Whaley-Connell A. T., Sowers J. R., Aldosterone and hypertension in the cardiometabolic syndrome. Journal of Clinical Hypertension 2008 10 2 94 96 2-s2.0-42049116590 10.1111/j.1751-7176.2008.08082.x
8. Cooper S. A., Whaley-Connell A., Habibi J., Wei Y., Lastra G., Manrique C., Stas S., Sowers J. R., Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. American Journal of Physiology 2007 293 4 H2009 H2023 2-s2.0-35148840913 10.1152/ajpheart.00522.2007 (Pubitemid 47605846)
9. Whaley-Connell A., Johnson M. S., Sowers J. R., Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Progress in Cardiovascular Diseases 2010 52 5 401 409 2-s2.0-77649291571 10.1016/j.pcad.2009.12.004
10. Williams J. S., Williams G., 50th anniversary of aldosterone. Journal of Clinical Endocrinology and Metabolism 2003 88 6 2364 2372 2-s2.0-0038482199 (Pubitemid 36724399)
11. Verrey F., Early aldosterone action: toward filling the gap between transcription and transport. American Journal of Physiology 1999 277 3 F319 F327 2-s2.0-0032887390 (Pubitemid 29459643)
12. Bhargava A., Pearce D., Mechanisms of mineralocorticoid action: determinants of receptor specificity and actions of regulated gene products. Trends in Endocrinology and Metabolism 2004 15 4 147 153 2-s2.0-1942518228 10.1016/j.tem.2004.03.009 (Pubitemid 38510493)
13. Kellner M., Peiter A., Hafner M., Feuring M., Christ M., Wehling M., Falkenstein E., Lösel R., Early aldosterone up-regulated genes: new pathways for renal disease? Kidney International 2003 64 4 1199 1207 2-s2.0-0141674967 10.1046/j.1523-1755.2003.00216.x (Pubitemid 37153784)
14. Féraille E., Doucet A., Sodium-potassium-adenosinetriphosphatase- dependent sodium transport in the kidney: hormonal control. Physiological Reviews 2001 81 1 345 418 2-s2.0-0035133295 (Pubitemid 32096179)
15. Reilly R. F., Ellison D. H., Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. Physiological Reviews 2000 80 1 277 313 2-s2.0-0033963206 (Pubitemid 30060566)
16. Farman N., Boulkroun S., Courtois-Coutry N., Sgk: an old enzyme revisited. Journal of Clinical Investigation 2002 110 9 1233 1234 2-s2.0-0036841715 10.1172/JCI200217064 (Pubitemid 35285747)
17. Garty H., Lindzen M., Scanzano R., Aizman R., Füzesi M., Goldshleger R., Farman N., Blostein R., Karlish S. J. D., A functional interaction between CHIF and Na-K-ATPase: implication for regulation by FXYD proteins. American Journal of Physiology 2002 283 4 F607 F615 2-s2.0-0036783541 (Pubitemid 35033947)
18. + Journal of the American Society of Nephrology 2003 14 5 1107 1115 2-s2.0-0345352652 10.1097/01.ASN.0000061777.67332.77 (Pubitemid 36514653)
19. Boulkroun S., Fay M., Zennaro M. C., Escoubet B., Jaisser F., Blot-Chabaud M., Farman N., Courtois-Coutry N., Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene. Journal of Biological Chemistry 2002 277 35 31506 31515 2-s2.0-0037199934 10.1074/jbc.M200272200 (Pubitemid 34968952)
20. Wehling M., Christ M., Theisen K., Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. American Journal of Physiology 1992 263 5 E974 E979 2-s2.0-0026458472
21. Funder J. W., The nongenomic actions of aldosterone. Endocrine Reviews 2005 26 3 313 321 2-s2.0-18844367745 10.1210/er.2005-0004 (Pubitemid 40686645)
22. Schiffrin E. L., Effects of aldosterone on the vasculature. Hypertension 2006 47 3 312 318 2-s2.0-33644987045 10.1161/01.HYP.0000201443.63240.a7 (Pubitemid 43740260)
23. Sowers J. R., Metabolic risk factors and renal disease. Kidney International 2007 71 8 719 720 2-s2.0-34247264495 10.1038/sj.ki.5002006 (Pubitemid 46624014)
24. Brown N. J., Aldosterone and vascular inflammation. Hypertension 2008 51 2 161 167 2-s2.0-38549092093 10.1161/HYPERTENSIONAHA.107.095489 (Pubitemid 351159920)
25. Schmidt B. M. W., Sammer U., Fleischmann I., Schlaich M., Delles C., Schmieder R. E., Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006 47 4 650 655 2-s2.0-33645838372 10.1161/01.HYP.0000205224.58715.cc (Pubitemid 43740234)
26. Chun T. Y., Howard Pratt J., Nongenomic renal effects of aldosterone: dependency on NO and genomic actions. Hypertension 2006 47 4 636 637 2-s2.0-33645827760 10.1161/01.HYP.0000205225.88721.2c (Pubitemid 43740227)
27. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G., Novello M., Favret G., Melis A., Cavarape A., Sechi L. A., Insulin sensitivity in patients with primary aldosteronism: a follow-up study. Journal of Clinical Endocrinology and Metabolism 2006 91 9 3457 3463 2-s2.0-33748752420 10.1210/jc.2006-0736 (Pubitemid 44402119)
28. Milliez P., Girerd X., Plouin P.-F., Blacher J., Safar M. E., michel.safar@htd.aphp.fr Mourad J.-J., Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 8 1243 1248 10.1016/j.jacc.2005.01.015 (Pubitemid 40523144)
29. González-Pérez P., stiefel@cica.es Stiefel P., Increased carotid intima-media thickness in hypertensive patients with a high aldosterone/plasma renin activity ratio and elevated aldosterone plasma concentration. Journal of Hypertension 2008 26 7 1499 1500 10.1097/HJH. 0b013e3282fd6932
30. Fallo F., Veglio F., Bertello C., Sonino N., Della Mea P., Ermani M., Rabbia F., Federspil G., Mulatero P., Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2006 91 2 454 459 2-s2.0-32544448025 10.1210/jc.2005-1733 (Pubitemid 43236909)
31. Fallo F., Della Mea P., Sonino N., Bertello C., Ermani M., Vettor R., Veglio F., Mulatero P., Adiponectin and insulin sensitivity in primary aldosteronism. American Journal of Hypertension 2007 20 8 855 861 2-s2.0-34547443383 10.1016/j.amjhyper.2007.03.012 (Pubitemid 47176347)
32. Giacchetti G., Ronconi V., Turchi F., Agostinelli L., Mantero F., Rilli S., Boscaro M., Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. Journal of Hypertension 2007 25 1 177 186 2-s2.0-33845358123 10.1097/HJH.0b013e3280108e6f (Pubitemid 44885680)
33. Colussi G., Catena C., Lapenna R., Nadalini E., Chiuch A., Sechi L. A., Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007 30 9 2349 2354 2-s2.0-34548419736 10.2337/dc07-0525 (Pubitemid 47359046)
34. Bochud M., Nussberger J., Bovet P., Maillard M. R., Elston R. C., Paccaud F., Shamlaye C., Burnier M., Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 2006 48 2 239 245 2-s2.0-33748141662 10.1161/01.HYP.0000231338.41548.fc (Pubitemid 44309818)
35. Kidambi S., Kotchen J. M., Grim C. E., Raff H., Mao J., Singh R. J., Kotchen T. A., Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 2007 49 3 704 711 2-s2.0-33847048251 10.1161/01.HYP.0000253258.36141.c7
36. Matrozova J., Steichen O., Amar L., Zacharieva S., Jeunemaitre X., Plouin P. F., Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009 53 4 605 610 2-s2.0-64849092310 10.1161/HYPERTENSIONAHA.108.122002
37. Egan B. M., eganbm@musc.edu Papademetriou V., Wofford M., Calhoun D., Fernandes J., Riehle J. E., Nesbitt S., Michelson E., Julius S., Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. American Journal of Hypertension 2005 18 1 3 12 10.1016/j.amjhyper.2004.08.008 (Pubitemid 40187342)
38. Sowers J. R., Whaley-Connell A., Epstein M., Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Annals of Internal Medicine 2009 150 11 776 783 2-s2.0-66549130863
39. Ehrhart-Bornstein M., Arakelyan K., Krug A. W., Scherbaum W. A., Bornstein S. R., Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocrine Research 2004 30 4 865 870 2-s2.0-11244311897 10.1081/ERC-200044122 (Pubitemid 40070185)
40. Kraus D., Jäger J., Meier B., Fasshauer M., Klein J., Aldosterone inhibits uncoupling protein-1, induces insulin resistance, and stimulates proinflammatory adipokines in adipocytes. Hormone and Metabolic Research 2005 37 7 455 459 2-s2.0-23144456873 10.1055/s-2005-870240 (Pubitemid 41081228)
41. Petrasek D., Jensen G., Tuck M., Stern N., In vitro effects of insulin on aldosterone production in rat zona glomerulosa cells. Life Sciences 1992 50 23 1781 1787 2-s2.0-0026506195 10.1016/0024-3205(92)90062-T
42. Dzau V. J., Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988 77 6 1 I-4 I-13 2-s2.0-0023922776
43. Min Ae Lee., Bohm M., Paul M., Ganten D., Tissue renin-angiotensin systems: their role in cardiovascular disease. Circulation 1993 87 5 4 IV7 IV13 2-s2.0-0002836379 (Pubitemid 23135644)
44. Engeli S., Negrel R., Sharma A. M., sharma@zedat.fu-berlin.de Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000 35 6 1270 1277 (Pubitemid 30413663)
45. Fallo F., Federspil G., Veglio F., Mulatero P., The metabolic syndrome in primary aldosteronism. Current Hypertension Reports 2007 9 2 106 111 2-s2.0-34248997189 10.1007/s11906-007-0019-1 (Pubitemid 46779374)
46. Sarzani R., Salvi F., Dessì-Fulgheri P., Rappelli A., Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. Journal of Hypertension 2008 26 5 831 843 2-s2.0-42149112825 10.1097/HJH.0b013e3282f624a0 (Pubitemid 351540757)
47. Engeli S., Gorzelniak K., Kreutz R., Runkel N., Distler A., Sharma A. M., Co-expression of renin-angiotensin system genes in human adipose tissue. Journal of Hypertension 1999 17 4 555 560 2-s2.0-0033026451 10.1097/00004872- 199917040-00014 (Pubitemid 29308566)
48. Cooper R., McFarlane-Anderson N., Bennett F. I., Wilks R., Puras A., Tewksbury D., Ward R., Forrester T., ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. Journal of Human Hypertension 1997 11 2 107 111 2-s2.0-0030908764 (Pubitemid 27202252)
49. Crandall D. L., Herzlinger H. E., Saunders B. D., Zolotor R. C., Feliciano L., Cervoni P., Identification and characterization of angiotensin II receptors in rat epididymal adipocyte membranes. Metabolism 1993 42 4 511 515 2-s2.0-0027481885 10.1016/0026-0495(93)90111-Z (Pubitemid 23112719)
50. Umemura S., Nyui N., Tamura K., Hibi K., Yamaguchi S., Nakamaru M., Ishigami T., Yabana M., Kihara M., Inoue S., Ishii M., Plasma angiotensinogen concentrations in obese patients. American Journal of Hypertension 1997 10 6 629 633 2-s2.0-18544397655 10.1016/S0895-7061(97)00053-8 (Pubitemid 27293478)
51. Eckel R. H., Grundy S. M., Zimmet P. Z., The metabolic syndrome. Lancet 2005 365 9468 1415 1428 2-s2.0-17144380822 10.1016/S0140-6736(05)66378-7 (Pubitemid 40523737)
52. Iyer S. N., Raizada M. K., Katovich M. J., AT1 receptor density changes during development of hypertension in hyperinsulinemic rats. Clinical and Experimental Hypertension 1996 18 6 793 810 2-s2.0-0029657980 (Pubitemid 26261093)
53. Goodfriend T. L., Ball D. L., Egan B. M., Campbell W. B., Nithipatikom K., Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004 43 2 358 363 2-s2.0-0842333052 10.1161/01.HYP.0000113294. 06704.64 (Pubitemid 38174139)
54. Goossens G. H., Blaak E. E., Van Baak M. A., Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obesity Reviews 2003 4 1 43 55 2-s2.0-0037300017 10.1046/j.1467-789X.2003.00091.x (Pubitemid 36356409)
55. Engeli S., Böhnke J., Gorzelniak K., Janke J., Schling P., Bader M., Luft F. C., Sharma A. M., Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005 45 3 356 362 2-s2.0-14644395574 10.1161/01.HYP. 0000154361.47683.d3 (Pubitemid 40315803)
56. Redon J., Cifkova R., Laurent S., Nilsson P., Narkiewicz K., Erdine S., Mancia G., Mechanisms of hypertension in the cardiometabolic syndrome. Journal of Hypertension 2009 27 3 441 451 2-s2.0-67149134992 10.1097/HJH. 0b013e32831e13e5
57. Grassi G., Dell'Oro R., Facchini A., Trevano F. Q., Bolla G. B., Mancia G., Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. Journal of Hypertension 2004 22 12 2363 2369 2-s2.0-10244267463 10.1097/00004872-200412000-00019 (Pubitemid 39620287)
58. Alvarez G. E., Beske S. D., Ballard T. P., Davy K. P., Sympathetic neural activation in visceral obesity. Circulation 2002 106 20 2533 2536 2-s2.0-0037069321 10.1161/01.CIR.0000041244.79165.25 (Pubitemid 35340687)
59. Ahima R. S., Adipose tissue as an endocrine organ. Obesity 2006 14 supplement 5 242S 249S 2-s2.0-34247556686 10.1038/oby.2006.317
60. da Silva A. A., Carmo J., Dubinion J., Hall J. E., The role of the sympathetic nervous system in obesity-related hypertension. Current Hypertension Reports 2009 11 3 206 211 2-s2.0-65749095507 10.1007/s11906-009-0036-3
61. Gomez-Sanchez E. P., Ahmad N., Romero D. G., Gomez-Sanchez C. E., Is aldosterone synthesized within the rat brain? American Journal of Physiology 2005 288 2 E342 E346 2-s2.0-12144285372 10.1152/ajpendo.00355.2004 (Pubitemid 40110641)
62. De Nicola A. F., Grillo C., Gonzalez S., Physiological, biochemical and molecular mechanisms of salt appetite control by mineralocorticoid action in brain. Brazilian Journal of Medical and Biological Research 1992 25 12 1153 1162 2-s2.0-0027075054 (Pubitemid 23037006)
63. Felder R. B., Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Experimental Physiology 2010 95 1 19 25 2-s2.0-74049150347 10.1113/expphysiol.2008.045948
64. Kontak A. C., Wang Z., Arbique D., Adams-Huet B., Auchus R. J., Nesbitt S. D., Victor R. G., Vongpatanasin W., wanpen.vongpatanasin@utsouthwestern.edu Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2010 95 10 4756 4761 10.1210/jc.2010-0823
65. Huang B. S., Ahmadi S., Ahmad M., White R. A., Leenen F. H., fleenen@ottawaheart.ca Central neuronal activation and pressor responses induced by circulating ANG II: role of the brain aldosterone-"ouabain" pathway. American Journal of Physiology 2010 299 2 H422 H430 10.1152/ajpheart.00256.2010
66. Huang B. S., White R. A., Ahmad M., Jeng A. Y., Leenen F. H., Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na in Wistar rats. American Journal of Physiology 2008 295 1 R166 R172 2-s2.0-50649107329 10.1152/ajpregu.90352.2008
67. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., Langenbach J., Willenberg H. S., Barthel A., Hauner H., McCann S. M., Scherbaum W. A., Bornstein S. R., Human adipocytes secrete mineralocorticoid-releasing factors. Proceedings of the National Academy of Sciences of the United States of America 2003 100 2 14211 14216 2-s2.0-10744220710 10.1073/pnas.2336140100 (Pubitemid 37499216)
68. Kurtz T. W., New treatment strategies for patients with hypertension and insulin resistance. American Journal of Medicine 2006 119 5, supplement 5 S24 S30 2-s2.0-33645106319 10.1016/j.amjmed.2006.01.011
69. Furuhashi M., Ura N., Higashiura K., Murakami H., Tanaka M., Moniwa N., Yoshida D., Shimamoto K., Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003 42 1 76 81 2-s2.0-0038818552 10.1161/01.HYP.0000078490.59735.6E (Pubitemid 36842239)
70. Ronconi V., Turchi F., Rilli S., Di Mattia D., Agostinelli L., Boscaro M., Giacchetti G., Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutrition, Metabolism and Cardiovascular Diseases 2010 20 2 93 100 2-s2.0-75349114561 10.1016/j.numecd.2009.03.007
71. Guo C., Ricchiuti V., Lian B. Q., Yao T. M., Coutinho P., Romero J. R., Li J., Williams G. H., Adler G. K., Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 2008 117 17 2253 2261 2-s2.0-44049097881 10.1161/CIRCULATIONAHA.107. 748640
72. Lamounier-Zepter V., Ehrhart-Bornstein M., Fat tissue metabolism and adrenal steroid secretion. Current Hypertension Reports 2006 8 1 30 34 2-s2.0-33646093249 10.1007/s11906-006-0038-3
73. Tuck M. L., Sowers J., Dornfeld L., The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. New England Journal of Medicine 1981 304 16 930 933 2-s2.0-0019424146 (Pubitemid 11101080)
74. Gordon R. D., Stowasser M., Tunny T. J., Klemm S. A., Rutherford J. C., High incidence of primary aldosteronism in 199 patients referred with hypertension. Clinical and Experimental Pharmacology and Physiology 1994 21 4 315 318 2-s2.0-0028216558 (Pubitemid 24201225)
75. Kaplan N. M., The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension 2004 22 5 863 869 2-s2.0-2542432149 10.1097/00004872-200405000-00001 (Pubitemid 38680454)
76. Stiefel P., Aparicio R., Carneado J., Pamies E., Villar J., The current epidemic of primary aldosteronism: causes and consequences. Journal of Hypertension 2004 22 10 2040 2042 2-s2.0-5044237606 (Pubitemid 39336690)
77. Stiefel P., García-Morillo J. S., Jimenez L., Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to- tetrahydrocortisone ratios in nonectopic Cushing's syndrome. Endocrine 2002 18 3 279 284 10.1385/ENDO:18:3:279 (Pubitemid 35239790)
78. Stiefel P., Carneado J., Cortisol, aldosterona y diferentes formas de hipertensión: papel de la 11-beta-hidroxiesteroide dehidrogenasa. Hipertensión 2000 17 4 161 168
79. Gimenez J., Stiefel P., Miranda M. L., Leal-Cerro A., Muniz O., Pamies E., Del val Martin-Sanz M., Villar J., Carneado J., The dispersion quotients: a new approach for evaluating the blood pressure profile in essential versus Cushing's syndrome hypertensive patients. Annals of the New York Academy of Sciences 1996 783 321 323 2-s2.0-0029848797 10.1111/j.1749-6632.1996.tb26731.x (Pubitemid 26372105)
80. Gaddam K. K., Nishizaka M. K., Pratt-Ubunama M. N., Pimenta E., Aban I., Oparil S., Calhoun D. A., Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Archives of Internal Medicine 2008 168 11 1159 1164 2-s2.0-45149100695 10.1001/archinte.168.11.1159 (Pubitemid 351831398)
81. Callera G. E., Touyz R. M., Tostes R. C., Yogi A., He Y., Malkinson S., Schiffrin E. L., Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005 45 4 773 779 2-s2.0-15744377168 10.1161/01.HYP.0000154365.30593.d3 (Pubitemid 40418380)
82. Prasad A., Quyyumi A. A., Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 2004 110 11 1507 1512 2-s2.0-4544333229 10.1161/01.CIR.0000141736.76561.78 (Pubitemid 39238031)
83. Hitomi H., Kiyomoto H., Nishiyama A., Hara T., Moriwaki K., Kaifu K., Ihara G., Fujita Y., Ugawa T., Kohno M., Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 2007 50 4 750 755 2-s2.0-34548850880 10.1161/HYPERTENSIONAHA.107.093955 (Pubitemid 47442741)
84. Wray D. W., Supiano M. A., Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension 2010 55 5 1217 1223 2-s2.0-77951451927 10.1161/HYPERTENSIONAHA.109.147058